

October 9, 2019

Dear Colleague,

For the 12th year, the Nevada Business Group on Health (NVBGH), Comagine Health (formerly *HealthInsight*), and iDo have partnered with Sanofi to produce the *Nevada Type 2 Diabetes Report™*, an overview of key demographic, utilization, charge, and pharmacotherapy measures for Type 2 diabetes patients in key local markets in Nevada. The report compares patients in profiled Nevada markets to each other, as well as to similar patients in Los Angeles, Salt Lake City, and across the nation. This year's edition—reformulated to better examine conditions that coexist with Type 2 diabetes—explores how these diagnoses impact care for the Type 2 diabetes patients who have them. As in previous editions, the report aims to help providers and employers identify opportunities to better serve the needs of their patients and employees.

Key findings in this year's report include:

- Among Las Vegas patients with Type 2 diabetes covered by commercial insurers, Medicare, or Medicaid, the percentages who received an A1c test in 2018 trailed the respective Los Angeles and Salt Lake City results.
- The shares of commercial or Medicaid patients with Type 2 diabetes whose A1c levels exceeded 9.0% were higher in Las Vegas, Reno, and statewide than they were in Los Angeles, Salt Lake City, and the nation in 2018.
- The percentage of Type 2 diabetes patients with more than two complications increased from 2017 to 2018 in Las Vegas, Reno, and across Nevada; this share surpassed the national benchmark in Las Vegas and Nevada in 2018.
- In 2018, Type 2 diabetes patients in Las Vegas and across Nevada were more apt than such patients nationally to have atherosclerotic cardiovascular disease (ASCVD), cardiovascular (CV) disease, myocardial infarction (MI), or peripheral artery disease (PAD).
- Nevada Type 2 diabetes patients with CV disease generated higher professional charges compared with the overall average, regardless of profiled setting.
- The shares of patients with Type 2 diabetes who also had stroke as a complication of their disease increased from 2017 to 2018 in Las Vegas, Reno, and statewide; in Las Vegas and Nevada, these portions exceeded those in Los Angeles, Salt Lake City, and the nation.
- Compared with similar patients in Los Angeles or Salt Lake City, those in Las Vegas with Type 2 diabetes had a greater chance of having a complication of hypoglycemia in 2018; emergency department professional charges for Las Vegas Type 2 diabetes patients with hypoglycemia were 64% higher than for such patients overall.
- Nearly 11% of Nevada patients with Type 2 diabetes also had depression in 2018, an increase from 9.4% the prior year; the percentage of such patients with an A1c >9.0% on their latest exam was higher than the overall benchmark for the state: 15.8% versus 14.7% in 2018.

NVBGH, Comagine Health, iDo, and Sanofi provide this report to once again call attention to potential unmet needs of patients with Type 2 diabetes and other chronic diseases. Please call or write us and join our interventions to achieve a healthier Nevada.

Sincerely,



Jerry Reeves, M.D.  
Medical Director  
Comagine Health